Year: 2025
Type: article
Abstract: Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) represents a significant global cause of visual impairment. Contemporary therapeutic approaches for neovascular AMD focus on inducing regression of CNV by inhibiting critical growth factors involved in angiogenesis. For nearly two decades, vascular endothelial growth factor (VEGF) has been the principal therapeutic target, with multiple intravitreally administered agents developed to achieve anatomical restoration and improved visual outcomes through sustained dosing.
DOI: 10.22336/rjo.2025.52
Authors: Ana-Maria Stoica, Sanda Jurja, Nejla Dervis
Institution: Ovidius University
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415361700
FWCI:
Cites:
Cited by:
Related to: